Abstract
No public abstract is available from the verified source records.
Open public full textRights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureZichao Luo
Open the manuscript using the link above. DOC files open in Word or a compatible document reader.
Abstract
Rights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
Open the manuscript using the link above. DOC files open in Word or a compatible document reader.
Authors
Institutions
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Open the manuscript using the link above. DOC files open in Word or a compatible document reader.
Intratumoral rhIL‐12 administration in head and neck squamous cell carcinoma patients induces B cell activation
10.1002/ijc.23756 · 2008
Improving cancer immunotherapy through nanotechnology
10.1038/s41568-019-0186-9 · 2019
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
10.1038/s41565-018-0342-5 · 2019
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
10.1038/s41563-022-01251-z · 2022
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
10.1038/s41565-018-0319-4 · 2019
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
10.1038/s41551-016-0011 · 2017
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses
10.1038/nmat2960 · 2011
Designer vaccine nanodiscs for personalized cancer immunotherapy
10.1038/nmat4822 · 2017
A STING-activating nanovaccine for cancer immunotherapy
10.1038/nnano.2017.52 · 2017
A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy
10.1038/s41565-020-00781-4 · 2020
Proton-driven transformable nanovaccine for cancer immunotherapy
10.1038/s41565-020-00782-3 · 2020
A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy
10.1038/s41565-022-01098-0 · 2022
Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy
10.1038/s41565-022-01245-7 · 2022
Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics
10.1038/s41565-022-01261-7 · 2023
Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety
10.1038/s41565-021-00982-5 · 2021
Bioinspired nanotopographical design of drug delivery systems
10.1038/s44222-022-00010-8 · 2023
No additional external references are available.